# A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

> **NCT02789345** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 29 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Necitumumab
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT02789345
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-24
- **Primary completion:** 2017-10-19
- **Final completion:** 2022-05-09
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02789345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02789345, "A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02789345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*